6.
Dinesh D, Chalupska D, Silhan J, Koutna E, Nencka R, Veverka V
. Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid phosphoprotein. PLoS Pathog. 2020; 16(12):e1009100.
PMC: 7735635.
DOI: 10.1371/journal.ppat.1009100.
View
7.
Korn S, Dhamotharan K, Jeffries C, Schlundt A
. The preference signature of the SARS-CoV-2 Nucleocapsid NTD for its 5'-genomic RNA elements. Nat Commun. 2023; 14(1):3331.
PMC: 10246530.
DOI: 10.1038/s41467-023-38882-y.
View
8.
Pontoriero L, Schiavina M, Korn S, Schlundt A, Pierattelli R, Felli I
. NMR Reveals Specific Tracts within the Intrinsically Disordered Regions of the SARS-CoV-2 Nucleocapsid Protein Involved in RNA Encountering. Biomolecules. 2022; 12(7).
PMC: 9312987.
DOI: 10.3390/biom12070929.
View
9.
Amicone M, Borges V, Alves M, Isidro J, Ze-Ze L, Duarte S
. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol Med Public Health. 2022; 10(1):142-155.
PMC: 8996265.
DOI: 10.1093/emph/eoac010.
View
10.
Deng X, Garcia-Knight M, Khalid M, Servellita V, Wang C, Morris M
. Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. Cell. 2021; 184(13):3426-3437.e8.
PMC: 8057738.
DOI: 10.1016/j.cell.2021.04.025.
View
11.
Mourier T, Shuaib M, Hala S, Mfarrej S, Alofi F, Naeem R
. SARS-CoV-2 genomes from Saudi Arabia implicate nucleocapsid mutations in host response and increased viral load. Nat Commun. 2022; 13(1):601.
PMC: 8807822.
DOI: 10.1038/s41467-022-28287-8.
View
12.
Wu H, Xing N, Meng K, Fu B, Xue W, Dong P
. Nucleocapsid mutations R203K/G204R increase the infectivity, fitness, and virulence of SARS-CoV-2. Cell Host Microbe. 2021; 29(12):1788-1801.e6.
PMC: 8590493.
DOI: 10.1016/j.chom.2021.11.005.
View
13.
Caruso I, Sanches K, Da Poian A, Pinheiro A, Almeida F
. Dynamics of the SARS-CoV-2 nucleoprotein N-terminal domain triggers RNA duplex destabilization. Biophys J. 2021; 120(14):2814-2827.
PMC: 8239202.
DOI: 10.1016/j.bpj.2021.06.003.
View
14.
Peng Y, Du N, Lei Y, Dorje S, Qi J, Luo T
. Structures of the SARS-CoV-2 nucleocapsid and their perspectives for drug design. EMBO J. 2020; 39(20):e105938.
PMC: 7560215.
DOI: 10.15252/embj.2020105938.
View
15.
Kang S, Yang M, Hong Z, Zhang L, Huang Z, Chen X
. Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm Sin B. 2020; 10(7):1228-1238.
PMC: 7194921.
DOI: 10.1016/j.apsb.2020.04.009.
View
16.
Keane S, Liu P, Leibowitz J, Giedroc D
. Functional transcriptional regulatory sequence (TRS) RNA binding and helix destabilizing determinants of murine hepatitis virus (MHV) nucleocapsid (N) protein. J Biol Chem. 2012; 287(10):7063-73.
PMC: 3293523.
DOI: 10.1074/jbc.M111.287763.
View
17.
Grossoehme N, Li L, Keane S, Liu P, Dann 3rd C, Leibowitz J
. Coronavirus N protein N-terminal domain (NTD) specifically binds the transcriptional regulatory sequence (TRS) and melts TRS-cTRS RNA duplexes. J Mol Biol. 2009; 394(3):544-57.
PMC: 2783395.
DOI: 10.1016/j.jmb.2009.09.040.
View
18.
Morse M, Sefcikova J, Rouzina I, Beuning P, Williams M
. Structural domains of SARS-CoV-2 nucleocapsid protein coordinate to compact long nucleic acid substrates. Nucleic Acids Res. 2022; 51(1):290-303.
PMC: 9841419.
DOI: 10.1093/nar/gkac1179.
View
19.
Estelle A, Forsythe H, Yu Z, Hughes K, Lasher B, Allen P
. RNA structure and multiple weak interactions balance the interplay between RNA binding and phase separation of SARS-CoV-2 nucleocapsid. PNAS Nexus. 2023; 2(10):pgad333.
PMC: 10605006.
DOI: 10.1093/pnasnexus/pgad333.
View
20.
Padroni G, Bikaki M, Novakovic M, Wolter A, Rudisser S, Gossert A
. A hybrid structure determination approach to investigate the druggability of the nucleocapsid protein of SARS-CoV-2. Nucleic Acids Res. 2023; 51(9):4555-4571.
PMC: 10201421.
DOI: 10.1093/nar/gkad195.
View